Biohit Oyj - Company Announcement

AMENDMENTS TO ARTICLES OF ASSOCIATION OF BIOHIT OYJ COME INTO POWER TODAY

BIOHIT OYJ STOCK EXCHANGE RELEASE ON 14 MAY 2010 AT 02:10 PM                    

AMENDMENTS TO THE ARTICLES OF ASSOCIATION OF BIOHIT OYJ COME INTO POWER TODAY 

The amendments to the Articles of Association of Biohit Oyj, decided by the AGM 
on 23 April 2010, have been registered and come into effect today, on 14 May    
2010.                                                                           

In accordance with the amendments, the term of Ainomaija Haarla, who was elected
as new member to the Board of Directors, begins today.                          

More information on the amendments made is available in the minutes of the  
AGM and the stock exchange release on 26 April 2010 (see                        
www.biohit.com/investors).                                                      



Further information:                                                            
Jussi Heiniö                                                                    
VP, Administration and Legal Affairs                                            
Tel: +358-9-773 861                                                             
Email: jussi.heinio@biohit.com                                                  


Distribution:                                                                   
NASDAQ OMX Helsinki Oy                                                          
Central storage facility (www.oam.fi)                                           
Press                                                                           
www.biohit.com                                                                  


About Biohit Oyj                                                                

Established in 1988, Biohit Oyj is a Finnish biotechnology company, acting on   
the global market. Biohit's operations are based on a goal-oriented and         
long-term innovation and patenting strategy.                                    
Biohit works with scientific communities to produce new technologies, products  
and services based on research results and innovations that can be used to      
develop safe and cost-effective liquid handling solutions for laboratory work as
well as diagnostic tests for the early detection and prevention of diseases of  
the gastrointestinal tract.                                                     

Biohit has two business segments: liquid handling and diagnostics. Liquid       
handling products include electronic and mechanical pipettes, disposable tips as
well as pipette maintenance and calibration services for research institutions, 
healthcare and industrial laboratories.                                         

The diagnostics business comprises products and analysis systems for the early  
diagnosis of gastrointestinal diseases, such as the blood-sample based          
GastroPanel examinations for the diagnosis of stomach illnesses and associated  
risks, quick tests for the diagnosis of lactose intolerance and H. pylori       
infection in connection with gastroscopy, and the ColonView examination for the 
early detection of intestinal bleeding that indicates a risk of colorectal      
cancer. The Acetium innovation reduces carcinogenic acetaldehyde in anacidic    
stomachs.                                                                       

The Biohit Group employs around 390 people. The company is headquartered in     
Helsinki, Finland, and has subsidiaries in France, Germany, the UK, Russia,     
India, China, Japan and the USA, as well as a representative office in          
Singapore. Additionally, Biohit's products are sold by approximately 450        
distributors in 70 countries.                                                   

Biohit's series B share (BIOBV) is quoted on NASDAQ OMX Helsinki, Small         
cap/Healthcare since 1999.                                                      

Read more at www.biohit.com